More than 300 global experts debate in Barcelona on the latest studies on genetic mutations and cancer.

Bellaterra, Cerdanyola del Vallès, 2011-July the researchers María Blasco, Director of the CNIO (National Cancer Center) and Manel Esteller, director of the programme of Epigenetics and cancer biology of the Institute of biomedical research of Bellvitge (PEBC-IDIBELL) have been responsible for opening and will also do likewise in the closing event, of the forty-first European Congress of mutagenesis, being these days from 4 to 7 July in Barcelona. The event has been organized by Dr. Jordi Surrallés, Professor of the Department of genetics and microbiology of the Universitat Autònoma de Barcelona (UAB) and member of the rare diseases Cyber (CIBERER), on behalf of the European Environmental Mutagen Society (EEMS).

A total of 65 conferences will be taught by world experts from different European countries, which presented recent studies on aspects of genomic stability, molecular Oncology, the origin of mutations, the effect and the detection of agents mutagenic and potential of cancer induction.

Presentations program is structured in ten sessions, including those dedicated to repair of the DNA, personalized therapy against cancer, rare diseases of tumor susceptibility, genotoxicity of nanoparticles, genetic toxicology in the pharmaceutical and chemical industries and studies of populations exposed to carcinogens.

Before the opening of the Congress, which was held at the Conventions Palace Barcelona Fair Centre Hotel, a meeting of labour statistics was held in genetic toxicology.

Through the Vice President for research, the UAB and the CIBERER are sponsors of the Congress, together with the Ministry of science and innovation, the genome Foundation Spain and AGAUR (Agency of management of aid University and research). Other institutions and pharmaceutical, chemical and biotech companies who have given their support to the meeting have been BioReliance, Covance, ECETOC (European Centre for Ecotoxicology and Toxicologic of Chemicals), Elsevier, CRF (Fonds der Chemischen Industrie), Hesi, Gentronix, Givaudan, GlaxoSmithKline, Harlan, Huntingdon, L ’ L’Oreal, MetaSystems, Novartis, Perceptive Instruments, Pfizer, Sanofi aventis, Trinova Biochem, UKEMS (United Kingdom Environmental Mutagen Society), and Unilever.

Agenda of the forty-first European Congress of mutagenesis

European Environmental Mutagen Society